JonesTrading Thinks Chimerix’s Stock is Going to Recover

JonesTrading analyst Soumit Roy maintained a Buy rating on Chimerix (CMRXResearch Report) today and set a price target of $14.00. The company’s shares closed last Friday at $4.24, close to its 52-week low of $3.34.

According to, Roy is a 3-star analyst with an average return of 3.2% and a 28.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.

Chimerix has an analyst consensus of Strong Buy, with a price target consensus of $19.33.

See today’s best-performing stocks on TipRanks >>

Based on Chimerix’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $46K and GAAP net loss of $39.5 million. In comparison, last year the company earned revenue of $1.12 million and had a GAAP net loss of $11.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Read More on CMRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More